Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz

İlknur Alsan Çetin; P. Öncü Yumuk; Beste Atasoy; Faysal Dane; Hale Çağlar; Roman İbrahimov; Hasan Batırel; Ufuk Abacıoğlu

-

Year 2012, Volume: 25 Issue: 2, 74 - 77, 17.03.2015

İlknur Alsan Çetin P. Öncü Yumuk Beste Atasoy , Faysal Dane Hale Çağlar Roman İbrahimov Hasan Batırel Ufuk Abacıoğlu

Abstract

Keywords

References

Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin
; 60: 277–300. doi: 10.3322/caac.20073
Sagar PM, Gauperaa T, Suc-Ling H, et al. An audit of the treatment of the
cancer of the oesophagus. Gut 1994; 35: 941-5.
Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on
esophageal carcinoma. Cancer 1996; 78: 1820-8. doi: 10.1002/
(SICI)1097-0142(19961015)78:8<1820
Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery
compared with surgery alone for localized esophageal cancer. N Eng J
Med 1998; 339:1979-84.
Herskovic A, Martz K, Al-Sarraf MV, et al. Combined chemotherapy and
radiotherapy compared with radiotherapy alone in patients with cancer
of the esophagus. N Eng J Med 1992; 326: 1593-8.
Boset JF, Gignoux M, Triboulet JP, et al. Chemoradiatherapy followed by
surgery compared with surgery alone in squamous cell cancer of the
esophagus. N Eng J Med 1997; 337: 161-7.
Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from
neoadjuvant chemoradiotherapy or chemotherapy in esophageal
carcinoma: a meta-analysis. Lancet Oncol 2007;8:226–34. doi:10.1016/
S1470-2045(07)70039-6
Greer SE, Goodney PP, Sutton JE, et al. Neoadjuvant chemoradiotherapy
for esophageal carcinoma: A meta-analysis. Surgery 2005; 137:172-7.
doi:10.1016/j.surg.2004.06.033
Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for
oesophageal cancer: A systematic review and meta-analysis. Gut 2004;
:925-30. doi:10.1136/gut.2003.025080
Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that
compared neoadjuvant chemoradiation and surgery to surgery alone for
resectable esophageal cancer. Am J Surg 2003;185:538-43.
doi:10.1016/S0002-9610(03)00066-7
Graham AJ, Shrive FM, Ghali WA, et al. Defining the optimal
treatment of locally advanced esophageal cancer: A systematic review
and decision analysis. Ann Thorac Surg 2007; 83:1257-64.
doi:10.1016/ j.athoracsur.2006.11.061
Coia LR, Engstrom PF, Paul AR, et al. Long-term results of infusional 5-FU,
mitomycin-C, and radiation as primary management of esophageal
carcinoma. Int J Radiat Oncol Biol Phys 1991;20:29-36.
doi:10.1016/0360-3016(91)90134-P
Wong RK, Malthaner RA, Zuraw L, et al. Cancer Care Ontario Practice
Guidelines Initiative Gastrointestinal Cancer Disease Site Group.
Combined modality radiotherapy and chemotherapy in nonsurgical
management of localized carcinoma of the esophagus: a practice
guideline. Int J Radiat Oncol Biol Phys 2003; 55:930-42. .
doi:10.1016/S0360-3016(02)04278-5
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally
advanced esophageal cancer: long-term follow-up of a prospective
randomized trial (RTOG 85-01). Radiation Therapy Oncology Group
JAMA. 1999; 281:1623-7.
al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined
chemoradiotherapy versus radiotherapy alone in patients with
esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-84.
Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery
compared with chemoradiation alone in squamous cancer of the
esophagus: FFCD 9102. J Clin Oncol 2007; 25:1160-8. doi:
1200/JCO.2005.04.7118
Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal
therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;
:462-7. doi: 10.1056/NEJM199608153350702
Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative
chemoradiation versus surgery alone in patients with locoregional
esophageal carcinoma. J Clin Oncol 2001;19:305-13.
Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus
chemoradiotherapy followed by surgery for resectable cancer of the
oesophagus: A randomised controlled phase III trial. Lancet Oncol
;6:659-68. doi:10.1016/S1470-2045(05)70288-6
Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality
therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared
with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol
;26:1086-92. Doi: 10.1200/JCO.2007.12.9593
Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy
Oncology Group 94-05) phase III trial of combined-modality therapy for
esophageal cancer: high-dose versus standard-dose radiation therapy. J
Clin Oncol 2002;20:1167-74.
Common Toxicity Criteria v.3.0. http://www.eortc.be/services/
doc/ctc/default.htm. Erişim tarihi 16.09.2011

Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz

Year 2012, Volume: 25 Issue: 2, 74 - 77, 17.03.2015

İlknur Alsan Çetin P. Öncü Yumuk Beste Atasoy , Faysal Dane Hale Çağlar Roman İbrahimov Hasan Batırel Ufuk Abacıoğlu

Abstract

Amaç: Bu çalışmada lokal ileri evre özefagus kanseri tanısıyla neoadjuvan/ definitif kemoradyoterapi (KRT) uygulanan hastaların sonuçlarının bildirilmesi amaçlanmıştır. Hastalar ve Yöntem: Histolojik tanısı skuamöz hücreli 10, adenokarsinom 4, adenoskuamöz karsinom 1 olan, T3N0M0 5 veya T3N1M0/T4N0M0 10, toplam 15 hasta geriye dönük olarak incelendi. Ortanca radyoterapi dozu 50 Gy (1,8-2 Gy/gün, 5 fraksiyon/hafta) olup eş zamanlı kemoterapi radyoterapinin ilk ve son hafta sisplatin ve 5-florourasil olarak uygulandı. Bulgular: Eş zamanlı kemoterapinin kesintisiz uygulanabilirlik oranı %80 idi. Medyan takip 15 ay (aralık, 3-70 ay) idi. Neoadjuvan olarak tedavi edilen beş hastadan birinde lokal progresyon, üçünde uzak metastaz izlendi. Baştan definitif KRT planlanan hastalardan üçüne (%30) evrede küçülme izlenerek cerrahi önerildi. İki yıllık lokal kontrol (LK) %22, uzak metastazsız sağkalım (UMSK) %45 ve genel sağkalım (GSK) %31 olarak saptandı. Derece III disfaji oranı %6 idi. Sonuç: Lokal ileri evre özefagus kanserinde tedavi tartışmalıdır. Cerrahi şansını elde eden hastalarda daha uzun sağkalım ve lokal kontrol bildirilirken üçlü modalite tedavilerin yapılabilirliği merkezin deneyimi ile sınırlıdır. Bu nedenle tüm hastalar bireysel olarak ve multidisipliner yaklaşım ile değerlendirilmelidir. (Marmara Üniversitesi Tıp Fakültesi Dergisi 2012;25:74-7)

Anahtar Kelimeler: Cerrahi, Lokal ileri evre, Kemoradyoterapi, Özefagus kanseri

Keywords

Cerrahi, Lokal ileri evre, Kemoradyoterapi, Özefaguskanseri

References

Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin
; 60: 277–300. doi: 10.3322/caac.20073
Sagar PM, Gauperaa T, Suc-Ling H, et al. An audit of the treatment of the
cancer of the oesophagus. Gut 1994; 35: 941-5.
Daly JM, Karnell LH, Menck HR. National Cancer Data Base report on
esophageal carcinoma. Cancer 1996; 78: 1820-8. doi: 10.1002/
(SICI)1097-0142(19961015)78:8<1820
Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery
compared with surgery alone for localized esophageal cancer. N Eng J
Med 1998; 339:1979-84.
Herskovic A, Martz K, Al-Sarraf MV, et al. Combined chemotherapy and
radiotherapy compared with radiotherapy alone in patients with cancer
of the esophagus. N Eng J Med 1992; 326: 1593-8.
Boset JF, Gignoux M, Triboulet JP, et al. Chemoradiatherapy followed by
surgery compared with surgery alone in squamous cell cancer of the
esophagus. N Eng J Med 1997; 337: 161-7.
Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from
neoadjuvant chemoradiotherapy or chemotherapy in esophageal
carcinoma: a meta-analysis. Lancet Oncol 2007;8:226–34. doi:10.1016/
S1470-2045(07)70039-6
Greer SE, Goodney PP, Sutton JE, et al. Neoadjuvant chemoradiotherapy
for esophageal carcinoma: A meta-analysis. Surgery 2005; 137:172-7.
doi:10.1016/j.surg.2004.06.033
Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for
oesophageal cancer: A systematic review and meta-analysis. Gut 2004;
:925-30. doi:10.1136/gut.2003.025080
Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that
compared neoadjuvant chemoradiation and surgery to surgery alone for
resectable esophageal cancer. Am J Surg 2003;185:538-43.
doi:10.1016/S0002-9610(03)00066-7
Graham AJ, Shrive FM, Ghali WA, et al. Defining the optimal
treatment of locally advanced esophageal cancer: A systematic review
and decision analysis. Ann Thorac Surg 2007; 83:1257-64.
doi:10.1016/ j.athoracsur.2006.11.061
Coia LR, Engstrom PF, Paul AR, et al. Long-term results of infusional 5-FU,
mitomycin-C, and radiation as primary management of esophageal
carcinoma. Int J Radiat Oncol Biol Phys 1991;20:29-36.
doi:10.1016/0360-3016(91)90134-P
Wong RK, Malthaner RA, Zuraw L, et al. Cancer Care Ontario Practice
Guidelines Initiative Gastrointestinal Cancer Disease Site Group.
Combined modality radiotherapy and chemotherapy in nonsurgical
management of localized carcinoma of the esophagus: a practice
guideline. Int J Radiat Oncol Biol Phys 2003; 55:930-42. .
doi:10.1016/S0360-3016(02)04278-5
Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally
advanced esophageal cancer: long-term follow-up of a prospective
randomized trial (RTOG 85-01). Radiation Therapy Oncology Group
JAMA. 1999; 281:1623-7.
al-Sarraf M, Martz K, Herskovic A, et al. Progress report of combined
chemoradiotherapy versus radiotherapy alone in patients with
esophageal cancer: an intergroup study. J Clin Oncol 1997;15:277-84.
Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery
compared with chemoradiation alone in squamous cancer of the
esophagus: FFCD 9102. J Clin Oncol 2007; 25:1160-8. doi:
1200/JCO.2005.04.7118
Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal
therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;
:462-7. doi: 10.1056/NEJM199608153350702
Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative
chemoradiation versus surgery alone in patients with locoregional
esophageal carcinoma. J Clin Oncol 2001;19:305-13.
Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus
chemoradiotherapy followed by surgery for resectable cancer of the
oesophagus: A randomised controlled phase III trial. Lancet Oncol
;6:659-68. doi:10.1016/S1470-2045(05)70288-6
Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality
therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared
with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol
;26:1086-92. Doi: 10.1200/JCO.2007.12.9593
Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy
Oncology Group 94-05) phase III trial of combined-modality therapy for
esophageal cancer: high-dose versus standard-dose radiation therapy. J
Clin Oncol 2002;20:1167-74.
Common Toxicity Criteria v.3.0. http://www.eortc.be/services/
doc/ctc/default.htm. Erişim tarihi 16.09.2011

There are 75 citations in total.

Details

Primary Language	Turkish
Journal Section	Articles
Authors	İlknur Alsan Çetin This is me P. Öncü Yumuk This is me Beste Atasoy Faysal Dane This is me Hale Çağlar This is me Roman İbrahimov This is me Hasan Batırel This is me Ufuk Abacıoğlu This is me
Publication Date	March 17, 2015
Published in Issue	Year 2012 Volume: 25 Issue: 2

Cite

APA	Alsan Çetin, İ., Öncü Yumuk, P., Atasoy, B., Dane, F., et al. (2015). Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz. Marmara Medical Journal, 25(2), 74-77.
AMA	Alsan Çetin İ, Öncü Yumuk P, Atasoy B, Dane F, Çağlar H, İbrahimov R, Batırel H, Abacıoğlu U. Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz. Marmara Med J. August 2015;25(2):74-77.
Chicago	Alsan Çetin, İlknur, P. Öncü Yumuk, Beste Atasoy, Faysal Dane, Hale Çağlar, Roman İbrahimov, Hasan Batırel, and Ufuk Abacıoğlu. “Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz”. Marmara Medical Journal 25, no. 2 (August 2015): 74-77.
EndNote	Alsan Çetin İ, Öncü Yumuk P, Atasoy B, Dane F, Çağlar H, İbrahimov R, Batırel H, Abacıoğlu U (August 1, 2015) Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz. Marmara Medical Journal 25 2 74–77.
IEEE	İ. Alsan Çetin, P. Öncü Yumuk, B. Atasoy, F. Dane, H. Çağlar, R. İbrahimov, H. Batırel, and U. Abacıoğlu, “Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz”, Marmara Med J, vol. 25, no. 2, pp. 74–77, 2015.
ISNAD	Alsan Çetin, İlknur et al. “Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz”. Marmara Medical Journal 25/2 (August 2015), 74-77.
JAMA	Alsan Çetin İ, Öncü Yumuk P, Atasoy B, Dane F, Çağlar H, İbrahimov R, Batırel H, Abacıoğlu U. Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz. Marmara Med J. 2015;25:74–77.
MLA	Alsan Çetin, İlknur et al. “Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz”. Marmara Medical Journal, vol. 25, no. 2, 2015, pp. 74-77.
Vancouver	Alsan Çetin İ, Öncü Yumuk P, Atasoy B, Dane F, Çağlar H, İbrahimov R, Batırel H, Abacıoğlu U. Lokal İleri Evre Özefagus Kanserinde Kemoradyoterapi Deneyimimiz. Marmara Med J. 2015;25(2):74-7.

Article Files

Full Text